Glucagonoma

Common Name(s)

Glucagonoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glucagonoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glucagonoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Glucagonoma" returned 50 free, full-text research articles on human participants. First 3 results:

Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report.
 

Author(s): David Graham Watt, Sanjay Pandanaboyana, Charles Simon Herrington, Iain S Tait

Journal:

 

Glucagonomas of the pancreas are neuroendocrine tumours (NETs) that arise from well-differentiated neuroendocrine cells within the pancreatic islets. They are considered to be aggressive NETs and often have metastases at initial presentation. In contrast localised glucagonoma without ...

Last Updated: 10 Sep 2013

Go To URL
Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.
 

Author(s): Stephanie A C Halvorson, Erin Gilbert, R Samuel Hopkins, Helen Liu, Charles Lopez, Michael Chu, Marie Martin, Brett Sheppard

Journal: J Gen Intern Med. 2013 Nov;28(11):1525-9.

 

Glucagonomas are slow-growing, rare pancreatic neuroendocrine tumors. They may present with paraneoplastic phenomena known together as the "glucagonoma syndrome." A hallmark sign of this syndrome is a rash known as necrolytic migratory erythema (NME). In this paper, the authors describe ...

Last Updated: 16 Oct 2013

Go To URL
[Diagnosis and treatment of glucagonoma: report of one case].
 

Author(s): Hong Cheng, Maoshan Chen, Guanglun Yang

Journal: Nan Fang Yi Ke Da Xue Xue Bao. 2013 Apr;33(4):618-insidebackcover.

 

glucagonoma is a rare islet alpha-cell tumor. We report a case of glucagonoma in a 55-year-old male patient with such clinical findings of necrolytic migratory erythema, diabetes mellitus, body weight loss, and anemia. CT examination found a space-occupying lesion in the pancreas, ...

Last Updated: 6 May 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Glucagonoma" returned 4 free, full-text review articles on human participants. First 3 results:

The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.
 

Author(s): Andre P van Beek, Ellen R M de Haas, Willem A van Vloten, Cees J M Lips, Janine F M Roijers, Marijke R Canninga-van Dijk

Journal: Eur. J. Endocrinol.. 2004 Nov;151(5):531-7.

 

The glucagonoma syndrome is a rare disease in which a typical skin disorder, necrolytic migratory erythema, is often one of the first presenting symptoms. Weight loss and diabetes mellitus are two other prevalent characteristics of this syndrome. Necrolytic migratory erythema belongs ...

Last Updated: 12 Nov 2004

Go To URL
Clinical experience in diagnosis and treatment of glucagonoma syndrome.
 

Author(s): Min Zhang, Xiao Xu, Yan Shen, Zhen-Hua Hu, Li-Ming Wu, Shu-Sen Zheng

Journal: HBPD INT. 2004 Aug;3(3):473-5.

 

Pancreatic endocrine tumors are uncommon neoplasms and can lead to systemic disorder including glucagonoma syndrome, a very rare prototypical paraneoplastic phenomenon. The aim of this study was to assess the diagnosis and surgical strategy for the treatment of glucagonoma syndrome.

Last Updated: 17 Aug 2004

Go To URL
Glucagonoma associated with calculous pancreatitis.
 

Author(s): C Mao, P M Pour, J M Howard

Journal: HPB Surg. 1996 ;9(2):77-81.

 

A Patient with a glucagonoma associated with calculous pancreatitis is reported. The authors know of only one other such patient. Because the calculous pancreatitis developed both upstream and downstream from the tumor, it cannot be attributed to obstruction of the pancreatic duct ...

Last Updated: 27 Jan 1997

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
 

Status: Recruiting

Condition Summary: Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; Endometrial Serous Adenocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Lung Carcinoid Tumor; Malignant Ovarian Mixed Epithelial Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Metastatic Gastrointestinal Neuroendocrine Tumor G1; Ovarian Carcinosarcoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Polypeptide Tumor; Recurrent Adult Liver Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Gastrointestinal Neuroendocrine Tumor G1; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Regional Gastrointestinal Neuroendocrine Tumor G1; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Corpus Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer; Uterine Carcinosarcoma

 

Last Updated: 15 Dec 2014

Go to URL
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
 

Status: Not yet recruiting

Condition Summary: Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma

 

Last Updated: 16 Oct 2014

Go to URL
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
 

Status: Recruiting

Condition Summary: Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma

 

Last Updated: 11 Nov 2014

Go to URL